Viropharma

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Viropharma ( VPHM) is engaged in the development and commercialization of products that address diseases, with a focus on products used by physician specialists or in hospital settings. This stock is trading up 6.4% at $30 in recent trading.

Today's Volume: 2.1 million

Average Volume: 1.1 million

Volume % Change: 178%

Shares of Viropharma are soaring today after the FDA announced it will allow them and Halozyme Therapeutics ( HALO) to resume clinical trials of a joint product they're developing.

From a technical perspective, VPHM is gapping up sharply here with heavy volume. This move has managed to push VPHM into breakout territory, since the stock has cleared some near-term overhead resistance at $28.49.

Traders should look to get long VPHM as long as it's trending above today's low of $29.03 and then once it sustains a move or close above $31.13 with volume that's near or above 1.1 million shares. If that breakout triggers soon, then VPHM will have a great chance of re-testing or possibly taking out its next major overhead resistance level at $33.17. Any high-volume move over $33.17 should be considered bullish action, since it will push VPHM into new 52-week high territory.

To see more stocks rising on unusual volume, check out the Stocks Rising On Unusual Volume portfolio on Stockpickr.

-- Written by Roberto Pedone in Winderemere, Fla.

RELATED LINKS:



Follow Stockpickr on Twitter and become a fan on Facebook.
At the time of publication, author had no positions in stocks mentioned.

Roberto Pedone, based out of Windermere, Fla., is an independent trader who focuses on stocks, options, futures, commodities and currencies. He is also an outside contributor to Beconequity.com and maintains the website Maddmoney.net, which he sold to Blue Wave Advisors in 2008. Roberto studied International Business at The Milwaukee School of Engineering, and he spent a year overseas studying business in Lubeck, Germany.

If you liked this article you might like

Zhongpin's Management Discusses Q2 2012 Results - Earnings Call Transcript

8 Stocks Soaring on High Volume

The 5 Dumbest Things on Wall Street This Week: April 13

The 5 Dumbest Things on Wall Street, April 13